Click below to download The Novozymes Report 2015 in PDF format.

  •  The big picture
  •  Our business
  •  Governance
  •  Accounts and performance
  •  Supplementary

The Novozymes Report 2015 is available in a full online version at The online report features interactive graphics and videos for a full multimedia experience.

Editorial team

Editor Anja Berg Winther, Corporate Communications | tel. +45 3077 0421
Finance Jens Breitenstein, Finance | tel. +45 4446 1087
Jan Paulsen, Finance | tel. +45 4446 3208
Investor Relations Martin Riise, Investor Relations | tel. +1 919 494 3483
Sustainability Maria Carlsen, Corporate Sustainability | tel. +45 3077 0121
Assistance Emilie Pai, Corporate Communications | tel. +45 3077 1278  
Amanda Howitz, Corporate Communications
Text The editorial team from Novozymes, headed by Corporate Communications
Photography  Lasse Bech Martinussen, Nana Reimers, Lars Just, and Thorbjørn Hansen 
Design & web Bysted A/S
Editing & proofreading

Borella projects  

© Novozymes A/S
Novozymes A/S | Krogshoejvej 36 | 2880 Bagsvaerd | Denmark

Reporting and audits

The website contains The Novozymes Report 2015 (which, pursuant to section 149 of the Danish Financial Statements Act, is an extract of the company's annual report) and the financial statements of the parent company Novozymes A/S. Together these form the company’s annual report, which will be filed with the Danish Business Authority.

PwC has audited the consolidated financial statements, the parent company financial statements, and environmental and social data. PwC has also been the sustainability assurance provider and has based the assurance on the AA1000 Assurance Standard (2008).

The audit covers financial, environmental and social data. These are marked “Audited by PwC.” See also the statements in the report.

PwC has not audited the sections of the report found under the headings The big picture, Our business, Governance and Supplementary reporting. The Supplementary reporting includes our Communication on Progress with respect to the UN Global Compact principles, our report index based on the Global Reporting Initiative (GRI), as well as detailed sustainability data from our activities in Argentina, Brazil, Canada, China, Denmark, India, the U.K. and the U.S.

The report has been produced in accordance with International Financial Reporting Standards (IFRS), the Danish Financial Statements Act and the additional requirements of Nasdaq Copenhagen A/S for the presentation of financial statements by listed companies. It has also been prepared as an element of Novozymes' reporting according to the GRI's G4 Sustainability Reporting Guidelines.

Forward-looking statements

This annual report contains forward-looking statements, including statements about future events, future financial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limited to, "believe," "anticipate," "expect," "estimate," "intend," "plan," "project," "could," "may," "might" and other words of similar meaning.

Forward-looking statements are by their very nature associated with risks and uncertainties that may cause actual results to differ materially from expectations, both positively and negatively. The risks and uncertainties may, among other things, include unexpected developments in i) the ability to develop and market new products; ii) the demand for Novozymes’ products, market-driven price decreases, industry consolidation, and launches of competing products or disruptive technologies in Novozymes’ core areas; iii) the ability to protect and enforce the company’s intellectual property rights; iv) significant litigation or breaches of contract; v) the materialization of the company’s growth platforms, notably the opportunity for marketing biomass conversion technologies or the development of microbial solutions for broad-acre crops; vi) political conditions, such as acceptance of enzymes produced by genetically modified organisms; vii) global economic and capital market conditions, including, but not limited to, currency exchange rates (USD/DKK and EUR/DKK in particular, but not exclusively), interest rates and inflation; viii) significant price decreases for inputs and materials that compete with Novozymes’ biological solutions. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.